27 related articles for article (PubMed ID: 34896914)
1. Epigenetic activation of METTL14 promotes docetaxel resistance in prostate cancer by promoting pri-microRNA-129 maturation.
Wu C; Miao C; Zhou S; Chang PA; He B; Zhou X; Tang Q
Environ Toxicol; 2024 Jun; 39(6):3734-3745. PubMed ID: 38546343
[TBL] [Abstract][Full Text] [Related]
2. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.
Zhou S; Wang B; Wei Y; Dai P; Chen Y; Xiao Y; Xia H; Chen C; Yin W
Cancer Biomark; 2024; 40(1):47-59. PubMed ID: 38306024
[TBL] [Abstract][Full Text] [Related]
3. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer.
Chen J; Wu Z; Ding W; Xiao C; Zhang Y; Gao S; Gao Y; Cai W
Theranostics; 2020; 10(4):1619-1632. PubMed ID: 32042326
[TBL] [Abstract][Full Text] [Related]
4. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer.
Chen L; Xu YX; Wang YS; Ren YY; Chen YM; Zheng C; Xie T; Jia YJ; Zhou JL
J Ethnopharmacol; 2024 Sep; 331():118265. PubMed ID: 38677579
[TBL] [Abstract][Full Text] [Related]
5. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
Veras ASC; Batista VRG; Correia RR; de Almeida Tavares ME; Rubira RJG; Tavares ER; Giometti IC; Maranhão RC; Teixeira GR
Sci Rep; 2024 Apr; 14(1):9626. PubMed ID: 38671015
[TBL] [Abstract][Full Text] [Related]
6. Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
Zhao J; Shen J; Mao L; Yang T; Liu J; Hongbin S
Oncogene; 2024 May; ():. PubMed ID: 38769193
[TBL] [Abstract][Full Text] [Related]
7. Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms.
Ahmadpour Youshanlui M; Nasiri H; Valedkarimi Z; Sadeghi M; Akbari M; Motlagh Asghari K; Jamali F; Abdi D; Mehramouz B; Rasi Bonab F; Baradaran B
Biochem Genet; 2024 May; ():. PubMed ID: 38722434
[TBL] [Abstract][Full Text] [Related]
8. Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells.
Canovai M; Evangelista M; Mercatanti A; D'Aurizio R; Pitto L; Marrocolo F; Casieri V; Pellegrini M; Lionetti V; Bracarda S; Rizzo M
Cell Death Discov; 2023 Dec; 9(1):445. PubMed ID: 38065937
[TBL] [Abstract][Full Text] [Related]
9. Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway.
Cheng J; Sun Y; Zhao H; Ren W; Gao D; Wang Z; Lv W; Dong Q
PeerJ; 2023; 11():e16314. PubMed ID: 38047026
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TYMSOS is a novel prognostic biomarker associated with immune infiltration in prostate cancer.
Xia Z; Wu J; Li Y; Yuan X; Sun J; Lv C; Huang P
Am J Cancer Res; 2023; 13(10):4531-4546. PubMed ID: 37970350
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of a redox-related long non-coding RNAs prognostic signature in head and neck squamous cell carcinoma.
Liu K; Huang T; Zhang H; Deng H; Tang M
Sci Rep; 2022 Dec; 12(1):22040. PubMed ID: 36543836
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications.
Zhou X; Ao X; Jia Z; Li Y; Kuang S; Du C; Zhang J; Wang J; Liu Y
Front Oncol; 2022; 12():951864. PubMed ID: 36059609
[TBL] [Abstract][Full Text] [Related]
13. LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer.
Zhang W; Xin J; Lai J; Zhang W
Immunobiology; 2022 Jan; 227(1):152163. PubMed ID: 34896914
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
15. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
16. LINC00184 plays an oncogenic role in non-small cell lung cancer via regulation of the miR-524-5p/HMGB2 axis.
Wang W; Li L; Zhao L
J Cell Mol Med; 2021 Nov; 25(21):9927-9938. PubMed ID: 34651416
[TBL] [Abstract][Full Text] [Related]
17. [LncRNA RPL22P1-201 affects prostate cancer cell proliferation, cell cycle, and sensitivity to docetaxel by regulating miR-216b-5p expression].
Yang C; Xue JG
Zhonghua Nan Ke Xue; 2023 Oct; 29(10):881-887. PubMed ID: 38639656
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
